Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Manczinger, Máté ^a   Kemény, Lajos ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CELECOXIB; CIMETIDINE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN A2; CYCLOHEXIMIDE; DEXAMETHASONE; FOLIC ACID; INDOMETACIN; INSULIN; LIOTHYRONINE; NIFEDIPINE; NORADRENALIN; PIOGLITAZONE; PROTEIN AR; PROTEIN KINASE FYN; PROTEIN MECOM; PROTEIN MEF2A; PROTEIN PIK3R1; RETINOIC ACID; RIFAMPICIN; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SELENIUM; TACROLIMUS; THEOPHYLLINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DP1; TRIPTOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; DISEASE PREDISPOSITION; GENE EXPRESSION; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; KERATINOCYTE; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; PATHOGENESIS; PHENOTYPE; POSITIVE FEEDBACK; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; PSORIASIS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; PROTEIN INTERACTION MAPS; PSORIASIS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSCRIPTOME;

EID: 84896718238     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080751     Document Type: Article

References (115)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133: 377-385.
2. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, et al. (2012) Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 44: 1341-1348.
3. Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271.
4. Farkas A, Kemeny L (2012) Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle. Int Immunopharmacol 13: 215-218.
5. Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol.
6. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182: 5836-5845.
7. Campain A, Yang YH (2010) Comparison study of microarray meta-analysis methods. BMC Bioinformatics 11: 408.
8. Barabasi AL, Albert R (1999) Emergence of scaling in random networks. Science 286: 509-512.
9. Brandes U, Erlebach T (2005) Network analysis: methodological foundations. Berlin; New York: Springer. xii, 471 p. p.
10. Ingram PJ, Stumpf MP, Stark J (2006) Network motifs: structure does not determine function. BMC Genomics 7: 108.
11. Kauffmann A, Gentleman R, Huber W (2009) arrayQualityMetrics - a bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415-416.
12. Servant N, Gravier E, Gestraud P, Laurent C, Paccard C, et al. (2010) EMA - A R package for Easy Microarray data analysis. BMC Res Notes 3: 277.
13. Kang DD, Sibille E, Kaminski N, Tseng GC (2012) MetaQC: objective quality control and inclusion/exclusion criteria for genomic meta-analysis. Nucleic Acids Res 40: e15.
14. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
15. Wang X, Kang DD, Shen K, Song C, Lu S, et al. (2012) An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics 28: 2534-2536.
16. Derkach A, Lawless JF, Sun L (2013) Robust and powerful tests for rare variants using Fisher's method to combine evidence of association from two or more complementary tests. Genet Epidemiol 37: 110-121.
17. Morgan AA, Khatri P, Jones RH, Sarwal MM, Butte AJ (2010) Comparison of multiplex meta analysis techniques for understanding the acute rejection of solid organ transplants. BMC Bioinformatics 11 Suppl 9: S6.
18. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561-568.
19. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, et al. (2012) STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 40: D876-880.
20. Robertson G, Bilenky M, Lin K, He A, Yuen W, et al. (2006) cisRED: a database system for genome-scale computational discovery of regulatory elements. Nucleic Acids Res 34: D68-73.
21. Wingender E, Dietze P, Karas H, Knuppel R (1996) TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 24: 238-241.
22. Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B (2004) JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res 32: D91-94.
23. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432.
24. Newman M (2005) Power laws, Pareto distributions and Zipf's law. Contemporary Physics 46: 323-351.
25. Li X, Stones DS, Wang H, Deng H, Liu X, et al. (2012) NetMODE: network motif detection without Nauty. PLoS One 7: e50093.
26. Ferro A, Giugno R, Pigola G, Pulvirenti A, Skripin D, et al. (2007) NetMatch: a Cytoscape plugin for searching biological networks. Bioinformatics 23: 910-912.
27. Nepusz T, Yu H, Paccanaro A (2012) Detecting overlapping protein complexes in protein-protein interaction networks. Nat Methods 9: 471-472.
28. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2: 2366-2382.
29. Maere S, Heymans K, Kuiper M (2005) BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21: 3448-3449.
30. Lu X, Jain VV, Finn PW, Perkins DL (2007) Hubs in biological interaction networks exhibit low changes in expression in experimental asthma. Mol Syst Biol 3: 98.
31. Arsic N, Bendris N, Peter M, Begon-Pescia C, Rebouissou C, et al. (2012) A novel function for Cyclin A2: control of cell invasion via RhoA signaling. J Cell Biol 196: 147-162.
32. Smyth D, Phan V, Wang A, McKay DM (2011) Interferon-gamma-induced increases in intestinal epithelial macromolecular permeability requires the Src kinase Fyn. Lab Invest 91: 764-777.
33. McCurdy CE, Schenk S, Holliday MJ, Philp A, Houck JA, et al. (2012) Attenuated Pik3r1 expression prevents insulin resistance and adipose tissue macrophage accumulation in diet-induced obese mice. Diabetes 61: 2495-2505.
34. Laug R, Fehrholz M, Schutze N, Kramer BW, Krump-Konvalinkova V, et al. (2012) IFN-gamma and TNF-alpha synergize to inhibit CTGF expression in human lung endothelial cells. PLoS One 7: e45430.
35. Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, et al. (2008) Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 47: 1924-1935.
36. Lai JJ, Lai KP, Zeng W, Chuang KH, Altuwaijri S, et al. (2012) Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am J Pathol 181: 1504-1512.
37. Kim WT, Kim H, Katanaev VL, Joon Lee S, Ishitani T, et al. (2012) Dual functions of DP1 promote biphasic Wnt-on and Wnt-off states during anteroposterior neural patterning. EMBO J 31: 3384-3397.
38. Roy S, Jorgensen HG, Roy P, Abed El Baky M, Melo JV, et al. (2012) BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Br J Haematol 157: 446-456.
39. Mora S, Pessin JE (2000) The MEF2A isoform is required for striated muscle-specific expression of the insulin-responsive GLUT4 glucose transporter. J Biol Chem 275: 16323-16328.
40. Ma'ayan A, Lipshtat A, Iyengar R, Sontag ED (2008) Proximity of intracellular regulatory networks to monotone systems. IET Syst Biol 2: 103-112.
41. Beutler B (2009) Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 227: 248-263.
42. Brandman O, Ferrell JE, Jr., Li R, Meyer T (2005) Interlinked fast and slow positive feedback loops drive reliable cell decisions. Science 310: 496-498.
43. Miller GC, Britt H (1995) A new drug classification for computer systems: the ATC extension code. Int J Biomed Comput 40: 121-124.
44. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-357.
45. Menter A, Griffiths CE (2007) Current and future management of psoriasis. Lancet 370: 272-284.
46. Brauchli YB, Jick SS, Curtin F, Meier CR (2008) Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol 58: 421-429.
47. Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S (2012) Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med 17: 171-176.
48. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, et al. (2000) Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136: 609-616.
49. Shirinsky IV, Shirinsky VS (2007) Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol 57: 529-531.
50. Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Rezaei Hemami M (2011) Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 31: 1045-1050.
51. Lebwohl M (1999) The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 38: 16-24.
52. de Jong EM, Menke HE, van Praag MC, van De Kerkhof PC (1999) Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 199: 313-318.
53. Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, et al. (2004) Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 50: 533-540.
54. Vali A, Asilian A, Khalesi E, Khoddami L, Shahtalebi M, et al. (2005) Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris. J Dermatolog Treat 16: 234-237.
55. Cohen AD, Kagen M, Friger M, Halevy S (2001) Calcium channel blockers intake and psoriasis: a case-control study. Acta Derm Venereol 81: 347-349.
56. Papakostantinou E, Xenos K, Markantonis SL, Druska S, Stratigos A, et al. (2005) Efficacy of 2 weeks' application of theophylline ointment in psoriasis vulgaris. J Dermatolog Treat 16: 169-170.
57. Gulliver WP, Donsky HJ (2005) A report on three recent clinical trials using Mahonia aquifolium 10% topical cream and a review of the worldwide clinical experience with Mahonia aquifolium for the treatment of plaque psoriasis. Am J Ther 12: 398-406.
58. Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U (2012) Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol 74: 424-436.
59. Tsankov N, Grozdev I (2011) Rifampicin - a mild immunosuppressive agent for psoriasis. J Dermatolog Treat 22: 62-64.
60. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, et al. (2008) Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 58: 625-631.
61. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, et al. (2001) Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 117: 1430-1436.
62. Kim TG, Byamba D, Wu WH, Lee MG (2011) Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment. Exp Dermatol 20: 855-857.
63. Sticozzi C, Belmonte G, Cervellati F, Di Capua A, Maioli E, et al. (2013) Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes. Eur J Pharm Sci 49: 133-141.
64. Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd Savoy L, et al. (2008) Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 128: 2606-2614.
65. Soler DC, McCormick TS (2011) The dark side of regulatory T cells in psoriasis. J Invest Dermatol 131: 1785-1786.
66. Tse WP, Cheng CH, Che CT, Lin ZX (2008) Arsenic trioxide, arsenic pentoxide, and arsenic iodide inhibit human keratinocyte proliferation through the induction of apoptosis. J Pharmacol Exp Ther 326: 388-394.
67. Santamaria LF, Torres R, Gimenez-Arnau AM, Gimenez-Camarasa JM, Ryder H, et al. (1999) Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes. J Invest Dermatol 113: 82-86.
68. Maioli E, Valacchi G (2010) Rottlerin: bases for a possible usage in psoriasis. Curr Drug Metab 11: 425-430.
69. Ikai K (1995) Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 32: 819.
70. Lamba G, Palaniswamy C, Singh T, Shah D, Lal S, et al. (2011) Psoriasis induced by losartan therapy: a case report and review of the literature. Am J Ther 18: e78-80.
71. Woo SM, Huh CH, Park KC, Youn SW (2007) Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol 34: 724-726.
72. Sendagorta E, Allegue F, Rocamora A, Ledo A (1987) Generalized pustular psoriasis precipitated by diclofenac and indomethacin. Dermatologica 175: 300-301.
73. Latini A, Carducci M (2003) Psoriasis during therapy with olanzapine. Eur J Dermatol 13: 404-405.
74. Tan Pei Lin L, Kwek SK (2010) Onset of psoriasis during therapy with fluoxetine. Gen Hosp Psychiatry 32: 446 e449-446 e410.
75. Schopf RE, Ockenfels HM, Schultewolter T, Morsches B (1993) Chloroquine stimulates the mitogen-driven lymphocyte proliferation in patients with psoriasis. Dermatology 187: 100-103.
76. Chiricozzi A, Saraceno R, Cannizzaro MV, Nistico SP, Chimenti S, et al. (2012) Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). Dermatology 225: 333-337.
77. Pisano C, Tambaro R, Di Maio M, Formato R, Iaffaioli VR, et al. (2004) Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. Arch Dermatol Res 296: 141-142.
78. Paslin D (1990) Psoriasis without neutrophils. Int J Dermatol 29: 37-40.
79. Cagiano R, Bera I, Vermesan D, Flace P, Sabatini R, et al. (2008) Psoriasis disappearance after the first phase of an oncologic treatment: a serendipity case report. Clin Ter 159: 421-425.
80. Halverstam CP, Lebwohl M (2008) Nonstandard and off-label therapies for psoriasis. Clin Dermatol 26: 546-553.
81. Perlman HH (1972) Remission of psoriasis vulgaris from the use of nerve-blocking agents. Arch Dermatol 105: 128-129.
82. Staples J, Klein D (2012) Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician 58: 404-408.
83. Zorzou MP, Stratigos A, Efstathiou E, Bamias A (2004) Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol 84: 308-309.
84. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, et al. (2012) Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One 7: e44274.
85. Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, et al. (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128: 110-124.
86. Buerger C, Malisiewicz B, Eiser A, Hardt K, Boehncke WH (2013) mTOR and its downstream signalling components are activated in psoriatic skin. Br J Dermatol.
87. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF (2013) NF-kappaB: An essential transcription factor in psoriasis. J Dermatol Sci 69: 89-94.
88. Hampton PJ, Jans R, Flockhart RJ, Parker G, Reynolds NJ (2012) Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2). J Cell Physiol 227: 1529-1537.
89. Choi JH, Choi DK, Sohn KC, Kwak SS, Suk J, et al. (2012) Absence of a human DnaJ protein hTid-1S correlates with aberrant actin cytoskeleton organization in lesional psoriatic skin. J Biol Chem 287: 25954-25963.
90. Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, et al. (2006) Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176: 1431-1438.
91. Buerger C, Richter B, Woth K, Salgo R, Malisiewicz B, et al. (2012) Interleukin-1beta interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol 132: 2206-2214.
92. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, et al. (2012) PSORS2 is due to mutations in CARD14. Am J Hum Genet 90: 784-795.
93. Kallimanis PG, Xenos K, Markantonis SL, Stavropoulos P, Margaroni G, et al. (2009) Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs. Clin Exp Dermatol 34: 582-586.
94. Madonna S, Scarponi C, Sestito R, Pallotta S, Cavani A, et al. (2010) The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kruppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol 185: 2467-2481.
95. Hald A, Andres RM, Salskov-Iversen ML, Kjellerup RB, Iversen L, et al. (2013) STAT1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol 168: 302-310.
96. Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, et al. (2011) Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 131: 108-117.
97. Jackson M, Howie SE, Weller R, Sabin E, Hunter JA, et al. (1999) Psoriatic keratinocytes show reduced IRF-1 and STAT-1alpha activation in response to gamma-IFN. FASEB J 13: 495-502.
98. Lee TW, Kwon H, Zong H, Yamada E, Vatish M, et al. (2013) Fyn Deficiency Promotes a Preferential Increase in Subcutaneous Adipose Tissue Mass and Decreased Visceral Adipose Tissue Inflammation. Diabetes.
99. Hwang MK, Kang NJ, Heo YS, Lee KW, Lee HJ (2009) Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha. Biochem Pharmacol 77: 1213-1222.
100. Giustizieri ML, Mascia F, Frezzolini A, De Pita O, Chinni LM, et al. (2001) Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107: 871-877.
101. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, et al. (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130: 1785-1796.
102. Senturk N, Aydin F, Birinci A, Yuksel EP, Kara N, et al. (2008) Investigation for the leptin 1 and LEP G2548A gene polymorphism in psoriasis. Eur J Dermatol 18: 343-344.
103. Michalik L, Wahli W (2007) Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 1771: 991-998.
104. Kwon YW, Jang ER, Lee YM, Kim YS, Kwon KS, et al. (2000) Insulin-like growth factor II induces interleukin-6 expression via NFkappaB activation in psoriasis. Biochem Biophys Res Commun 278: 312-317.
105. Schwarz W, Schell H, Hornstein OP (1981) Testosterone serum levels in male psoriatics. Arch Dermatol Res 270: 377-379.
106. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114: 154-163.
107. Wang TS, Tsai TF (2012) Intralesional therapy for psoriasis. J Dermatolog Treat.
108. Kohn D, Flatau E, Daher O, Zuckerman F (1980) Treatment of psoriasis with daunorubicin and cytarabine. Arch Dermatol 116: 1101-1102.
109. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, et al. (1998) Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7: 81-96.
110. Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, et al. (2009) Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 129: 2795-2804.
111. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, et al. (2008) Type I interferon: potential therapeutic target for psoriasis? PLoS One 3: e2737.
112. (!!! INVALID CITATION !!!).
113. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, et al. (2012) Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132: 2552-2564.
114. Reischl J, Schwenke S, Beekman JM, Mrowietz U, Sturzebecher S, et al. (2007) Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 127: 163-169.
115. Johnson-Huang LM, Pensabene CA, Shah KR, Pierson KC, Kikuchi T, et al. (2012) Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs. PLoS One 7: e30308.